Indolent systemic mastocytosis is a lifelong condition where abnormal mast cells accumulate mainly in the bone marrow and sometimes in other organs like the skin, causing a wide range of symptoms that can significantly affect daily life. While there is currently no cure for this rare disorder, various treatment approaches exist to help manage symptoms and improve quality of life, from established medications used for many years to promising new therapies being tested in ongoing clinical trials.

Understanding Treatment Goals for Indolent Systemic Mastocytosis

When it comes to treating indolent systemic mastocytosis, healthcare providers focus on several important goals. The main aim is to control the symptoms caused by excessive release of chemicals from mast cells, such as itching, flushing, digestive problems, and potentially dangerous allergic reactions. Another key goal is to prevent life-threatening anaphylaxis, which people with this condition face at higher risk than the general population. Treatment also addresses specific complications like bone weakness or stomach ulcers that can develop over time.^[1][8]

The treatment approach for indolent systemic mastocytosis depends heavily on individual patient characteristics. Doctors consider the severity of symptoms, which organs are affected, and whether the person has experienced severe allergic reactions. Some patients may have relatively mild symptoms that can be managed with simple measures, while others require more intensive treatment strategies. The disease typically progresses slowly over many years, which means treatment plans often need to be adjusted as symptoms evolve.^[1][2]

Current medical guidelines recommend a combination of approaches. These include standard treatments that have been used successfully for years and are approved by medical societies worldwide. At the same time, researchers are actively investigating new therapies through clinical trials, offering hope for better symptom control and quality of life. Understanding both established and experimental options helps patients and their healthcare teams make informed decisions about the most appropriate treatment path.^[8][14]

Standard Treatment Approaches

The foundation of treating indolent systemic mastocytosis involves managing the release of chemicals from mast cells and preventing severe allergic reactions. Antihistamines represent the first line of defense for many patients. These medications work by blocking the effects of histamine, one of the main chemicals released by mast cells. Healthcare providers typically prescribe both H1 antihistamines, which help with itching, flushing, and skin symptoms, and H2 antihistamines, which target digestive problems and stomach acid production. Patients might use non-sedating antihistamines like cetirizine or desloratadine during the day, and sedating ones like diphenhydramine or hydroxyzine at bedtime to help with sleep disrupted by itching.^[8][14]

For digestive symptoms that persist despite antihistamines, doctors often add medications called proton pump inhibitors to reduce stomach acid and prevent ulcers. Another medication called sodium cromoglicate, which is a mast cell stabilizer, has shown benefits for relieving abdominal pain, diarrhea, and even cognitive symptoms that some patients experience. This medication works by reducing the amount of chemicals released by mast cells, though it is not well absorbed from the bowel. Some patients report improvement in multiple symptoms when taking sodium cromoglicate regularly.^[8][11][14]

Skin lesions, which commonly appear in indolent systemic mastocytosis, can be treated with topical corticosteroid creams. These strong steroid preparations are applied directly to affected areas of skin for limited periods to reduce the number of mast cells and decrease inflammation. However, prolonged use can cause side effects including skin thinning, stretch marks, and changes in skin color, so doctors carefully monitor this treatment. For more severe skin symptoms not controlled by creams, some patients may benefit from psoralen plus ultraviolet A therapy, known as PUVA. This treatment combines a medication that makes skin more sensitive to light with exposure to specific ultraviolet wavelengths, which can reduce lesions and itching. Patients can only receive a limited number of PUVA sessions due to long-term cancer risk.^[11][14]

When indolent systemic mastocytosis affects bone health, causing osteoporosis or fractures, treatment includes medications called bisphosphonates. These drugs slow down bone breakdown while allowing new bone formation to continue, improving bone density over time. Patients typically receive calcium supplements alongside bisphosphonates, as calcium is essential for bone strength. For severe bone pain, short courses of oral corticosteroids may be prescribed, though doctors use these cautiously due to potential side effects including increased appetite, weight gain, insomnia, fluid retention, and mood changes.^[8][11]

Leukotriene antagonists, medications originally developed for asthma such as montelukast and zafirlukast, have also been used in managing systemic mastocytosis symptoms. These drugs block another chemical pathway involved in allergic reactions. For patients experiencing severe flushing that does not respond to antihistamines, aspirin can sometimes be helpful, though this must be carefully considered as some patients with mastocytosis may have adverse reactions to aspirin.^[14]

The duration of treatment for indolent systemic mastocytosis is typically lifelong, as this is a chronic condition. Patients work closely with their healthcare teams to adjust medications based on symptom patterns and any new complications that develop. Regular follow-up appointments help monitor disease progression and treatment effectiveness. Side effects from standard treatments are generally manageable but require ongoing attention, particularly with long-term use of antihistamines, which can cause drowsiness, dry mouth, and headaches in some individuals.^[1][8]

Emerging Treatments in Clinical Trials

Research into new treatments for indolent systemic mastocytosis has advanced significantly, with several promising therapies currently being evaluated in clinical trials. These experimental approaches target the underlying genetic mutations and biological mechanisms that drive the disease, potentially offering more comprehensive symptom control than traditional medications.^[4][8]

One of the most important developments involves medications called tyrosine kinase inhibitors. These drugs work by blocking specific enzymes that control mast cell growth and survival. The most common genetic mutation in indolent systemic mastocytosis, known as KIT D816V, is found in approximately 95% of patients. This mutation causes a protein called KIT to remain constantly activated like a switch stuck in the “on” position, leading to uncontrolled mast cell proliferation and activation. Tyrosine kinase inhibitors that can target this specific mutation represent a major breakthrough in treatment possibilities.^[3][7][9]

Masitinib has emerged as a leading experimental treatment specifically developed for mastocytosis. This drug received orphan drug designation from both the European Medicine Agency and the U.S. Food and Drug Administration, which recognizes the critical need for new treatments for this rare condition. Masitinib works through its inhibitory action on wild-type c-Kit, as well as Lyn and Fyn tyrosine kinases, reducing mast cell activity. Clinical trials have tested masitinib in different groups of patients, including those with and without the D816V mutation.^[4]

Results from Phase 2 clinical trials of masitinib showed encouraging outcomes. In one study of patients carrying the D816V mutation, participants experienced significant improvements in key symptoms after 12 weeks of treatment. The frequency of flushing episodes decreased by 55%, depression scores improved by 49%, and itching reduced by 45%. In another study involving patients without the D816V mutation, flushing decreased by 64%, depression improved by 43%, and itching reduced by 36%. These studies enrolled a total of 46 patients and demonstrated that masitinib could provide meaningful symptom relief across different patient populations.^[4]

Building on these early results, a Phase 3 clinical trial of masitinib was conducted to confirm its effectiveness compared to standard treatment. This larger study showed that masitinib was superior to the comparator medication, as measured by the cumulative response rate in severely symptomatic patients with indolent or smoldering systemic mastocytosis. The Phase 3 trial represented a major step forward in establishing masitinib as a potential new treatment option for patients who continue to experience significant symptoms despite conventional therapy.^[4]

Avapritinib, marketed as AYVAKIT, represents another important advance in targeted therapy for systemic mastocytosis. This medication is a selective KIT D816V inhibitor, meaning it specifically targets the most common mutation found in this disease. The U.S. Food and Drug Administration approved avapritinib for adults with indolent systemic mastocytosis, making it the first and only FDA-approved treatment specifically for this condition. This approval marked a significant milestone, as historically patients could only manage individual symptoms rather than target the underlying disease process.^[7]

The mechanism of action of avapritinib involves directly blocking the abnormal KIT protein produced by the D816V mutation. By inhibiting this constantly activated protein, avapritinib can reduce both the number of abnormal mast cells and their tendency to release excessive amounts of chemicals. Clinical trials of avapritinib have shown that it can help reduce various symptoms across multiple organ systems, potentially addressing the wide-ranging impact of indolent systemic mastocytosis on patients’ lives.^[7]

For patients with more advanced forms of systemic mastocytosis, another medication called midostaurin has been developed. While primarily used for advanced disease, midostaurin is active against both wild-type and mutant KIT D816V, offering a broader range of action. This drug has been approved for treating advanced systemic mastocytosis, and ongoing research continues to evaluate its potential role in different patient populations.^[8][12]

Omalizumab, a humanized monoclonal antibody that works differently from tyrosine kinase inhibitors, has shown promise in clinical studies for patients with treatment-resistant mastocytosis. This medication binds to IgE antibodies, preventing them from attaching to mast cells and triggering the release of inflammatory chemicals. In patients with indolent systemic mastocytosis who experience recurrent anaphylaxis despite optimal preventive therapy with antihistamines, omalizumab reduced the frequency of severe allergic reactions. Long-term treatment with omalizumab has been reported to successfully control vasomotor symptoms including anaphylaxis, though it may be less effective for respiratory, musculoskeletal, and neuropsychiatric symptoms. This use of omalizumab is considered off-label, meaning it is not officially approved for mastocytosis but is recommended by expert medical societies based on clinical evidence.^[8][13][14]

Another medication being investigated is interferon alpha, originally developed for cancer treatment. This drug appears to reduce the production of mast cells in the bone marrow, though the exact mechanism is not fully understood. Interferon alpha is given by injection and has been used in some cases of aggressive mastocytosis. When patients start taking interferon alpha, they commonly experience flu-like symptoms including chills, fever, and joint pain, though these typically improve as the body adjusts to the medication.^[11]

Cladribine, a purine analog medication, represents another treatment approach being studied. This drug has significant activity against monocytes, cells thought to share a common origin with mast cells. Cladribine has shown effectiveness in some patients with systemic mastocytosis, though its use is typically reserved for more advanced or treatment-resistant cases. Research continues to define the optimal role for cladribine in the treatment landscape.^[8]

Clinical trials for indolent systemic mastocytosis typically proceed through several phases. Phase I trials focus primarily on safety, testing the medication in a small number of people to identify appropriate doses and watch for serious side effects. Phase II trials evaluate effectiveness, determining whether the treatment actually helps control symptoms and affects disease markers. These studies involve larger numbers of patients and provide preliminary evidence of benefit. Phase III trials compare the new treatment with current standard care in even larger patient groups, providing the strongest evidence needed for regulatory approval. Patients interested in participating in clinical trials can contact research centers or pharmaceutical companies conducting studies.^[4]

Eligibility for clinical trials varies depending on the specific study requirements. Generally, trials seek patients with confirmed diagnoses of indolent or smoldering systemic mastocytosis who continue to have moderate to severe symptoms despite standard treatment. Some trials may require specific genetic test results, while others might include patients with or without certain mutations. Trials are conducted in various locations including academic medical centers in the United States, Europe, and other regions. Patients considering clinical trial participation should discuss the potential benefits and risks with their healthcare team, as experimental treatments may have unknown side effects or may not provide benefit.^[4]

Most Common Treatment Methods

• Antihistamine Therapy
  • H1 antihistamines (cetirizine, desloratadine, diphenhydramine, hydroxyzine) to control itching, flushing, and skin symptoms
  • H2 antihistamines to manage gastric hypersecretion and prevent peptic ulcers
  • Non-sedating formulations for daytime use and sedating ones for nighttime symptom control
• Mast Cell Stabilizers
  • Sodium cromoglicate (cromolyn sodium) for abdominal pain, diarrhea, pruritus, whealing, flushing, and cognitive impairment
  • Reduces chemical mediator release from mast cells
• Proton Pump Inhibitors
  • Manage gastric hypersecretion and peptic ulcer disease associated with mastocytosis
  • Used alongside H2 receptor blockers for digestive symptoms
• Topical and Systemic Corticosteroids
  • Topical corticosteroid creams for cutaneous lesions, applied for limited periods
  • Oral corticosteroids for malabsorption, ascites, refractory abdominal pain, bone pain, or severe cutaneous disease
  • Short-term use to prevent anaphylaxis in specific situations
• Emergency Anaphylaxis Treatment
  • Epinephrine auto-injectors prescribed for all patients due to high anaphylaxis risk
  • Patient and family training on recognition of symptoms and proper use of auto-injector
  • Immediate administration for severe allergic reactions
• Bone Health Management
  • Bisphosphonates to slow bone breakdown and improve bone density
  • Calcium supplements to strengthen bones
  • Treatment for osteoporosis and prevention of fractures
• Phototherapy
  • Psoralen plus ultraviolet A (PUVA) therapy for severe skin symptoms
  • Provides transient relief of pruritus and fading of skin lesions
  • Limited number of sessions due to long-term cancer risk
• Tyrosine Kinase Inhibitors
  • Masitinib: inhibits wild-type c-Kit, Lyn, and Fyn tyrosine kinases; tested in Phase 2 and Phase 3 trials with positive results
  • Avapritinib (AYVAKIT): FDA-approved selective KIT D816V inhibitor for adults with indolent systemic mastocytosis
  • Midostaurin: active against wild-type and mutant KIT D816V, approved for advanced systemic mastocytosis
• Immunomodulatory Agents
  • Omalizumab (anti-IgE antibody): off-label use for recurrent anaphylaxis despite optimal preventive therapy
  • Interferon alpha: reduces mast cell production in bone marrow, used in some refractory cases
• Additional Symptom Management
  • Leukotriene antagonists (montelukast, zafirlukast) for various symptoms
  • Aspirin for flushing unresponsive to antihistamines in selected patients
  • Anticholinergics for diarrhea management
• Venom Immunotherapy
  • Mandatory for patients with documented Hymenoptera (insect) venom allergy
  • Reduces risk of severe anaphylaxis from insect stings